Incyte Corp. (INCY)

85.19
0.48 0.57
NASDAQ : Health Technology
Prev Close 84.71
Open 85.26
Day Low/High 85.02 / 87.54
52 Wk Low/High 80.85 / 153.15
Volume 1.31M
Avg Volume 1.60M
Exchange NASDAQ
Shares Outstanding 211.66M
Market Cap 18.21B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 2018 RBC Capital Markets Global Healthcare Conference on Wednesday, February 21, 2018 at 11:00 am (ET) in New York.

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of Incyte's common stock at a price of $88.

Incyte Moves Up In Analyst Rankings, Passing Fidelity National Information Services

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #79 spot from Fidelity National Information Services Inc , according to ETF Channel. Below is a chart of Incyte Corporation versus Fidelity National Information Services Inc plotting their respective rank within the S&P 500 over time (INCY plotted in blue; FIS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 36 th Annual J.

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Verisk Analytics

The most recent short interest data has been released for the 11/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Four-Year Phase 3 Data Analysis Shows Durability Of Response Of Jakafi® (ruxolitinib) In Patients With Polycythemia Vera

Four-Year Phase 3 Data Analysis Shows Durability Of Response Of Jakafi® (ruxolitinib) In Patients With Polycythemia Vera

Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year) follow-up data from the ongoing, global, multi-center, open-label Phase 3 RESPONSE study of Jakafi ® (ruxolitinib) comparing the efficacy and...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVH, FBIZ, FLWS, NWSA, RPM Downgrades: EQS, FRAN, FUNC, GVP, INCY, MPAA, OXBR, PCTY, SNFCA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Incyte Announces Initiation Of Pivotal Clinical Trial Of Ruxolitinib (Jakafi®) For The Treatment Of Essential Thrombocythemia

Incyte Announces Initiation Of Pivotal Clinical Trial Of Ruxolitinib (Jakafi®) For The Treatment Of Essential Thrombocythemia

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi ®) compared to anagrelide for the treatment of patients with essential...

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Jim Cramer highlights Apache, Incyte, Prudential, and ON Semiconductor in the Lightning Round.

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Jim Cramer says the playing field is all digital, and companies need the best technology when competitors like Amazon are both enemy and ally at the same time.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated With Baricitinib Reported Greater Improvements In Pain Compared To Adalimumab Or Placebo

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated With Baricitinib Reported Greater Improvements In Pain Compared To Adalimumab Or Placebo

- Post-hoc analysis presented at ACR/ARHP shows pain improvement was consistent regardless of a patient's baseline pain severity

More Than 30 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 59th Annual ASH Meeting

More Than 30 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 59th Annual ASH Meeting

Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts including data from its clinical development programs for Jakafi ® (ruxolitinib), JAK1, PI3Kd, PIM and BRD will be presented at the upcoming...

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 third-quarter financial results, highlighting 38 percent year-on-year growth in product-related revenue, driven by increased sales of Jakafi ® (ruxolitinib) in the U.

Incyte And AstraZeneca To Enter Clinical Trial Collaboration In Early Lung Cancer

Incyte And AstraZeneca To Enter Clinical Trial Collaboration In Early Lung Cancer

Incyte Corporation (Nasdaq:INCY) and MedImmune, AstraZeneca's (NYSE:AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration.

Incyte Names New Member To Its Board Of Directors

Incyte Names New Member To Its Board Of Directors

Incyte Corporation (Nasdaq:INCY) today announced the appointment of Jacqualyn "Jackie" A.

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics Soars on Collaboration with Incyte -- Biotech Movers

MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.

Incyte And MacroGenics Announce Global Collaboration And Licensing Agreement For Anti-PD-1 Monoclonal Antibody MGA012

Incyte And MacroGenics Announce Global Collaboration And Licensing Agreement For Anti-PD-1 Monoclonal Antibody MGA012

Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational...

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 26 th Annual Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 9:45am (MST) in Scottsdale, Arizona.

Incyte To Report Third Quarter Financial Results

Incyte To Report Third Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.

Incyte And Cancer Support Community Delaware Announce The Establishment Of The Incyte Cancer Care Assistance Fund For Delaware

Incyte And Cancer Support Community Delaware Announce The Establishment Of The Incyte Cancer Care Assistance Fund For Delaware

Incyte Corporation (Nasdaq:INCY) and Cancer Support Community Delaware (CSCDE) today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for...

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Progression-Free Survival Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma

Progression-Free Survival Data From ECHO-202 Trial Of Incyte's Epacadostat In Combination With Merck's KEYTRUDA® (pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte's...

TheStreet Quant Rating: D+ (Sell)